Astria Therapeutics (ATXS) Competitors $9.55 -0.12 (-1.24%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ATXS vs. CNTA, RXRX, APGE, IBRX, WVE, MIRM, AKRO, TARS, AMPH, and IRONShould you be buying Astria Therapeutics stock or one of its competitors? The main competitors of Astria Therapeutics include Centessa Pharmaceuticals (CNTA), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), ImmunityBio (IBRX), Wave Life Sciences (WVE), Mirum Pharmaceuticals (MIRM), Akero Therapeutics (AKRO), Tarsus Pharmaceuticals (TARS), Amphastar Pharmaceuticals (AMPH), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Astria Therapeutics vs. Centessa Pharmaceuticals Recursion Pharmaceuticals Apogee Therapeutics ImmunityBio Wave Life Sciences Mirum Pharmaceuticals Akero Therapeutics Tarsus Pharmaceuticals Amphastar Pharmaceuticals Disc Medicine Centessa Pharmaceuticals (NASDAQ:CNTA) and Astria Therapeutics (NASDAQ:ATXS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment. Which has more risk and volatility, CNTA or ATXS? Centessa Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, Astria Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Do insiders and institutionals believe in CNTA or ATXS? 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.0% of Astria Therapeutics shares are owned by institutional investors. 11.6% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 2.9% of Astria Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor CNTA or ATXS? In the previous week, Centessa Pharmaceuticals had 7 more articles in the media than Astria Therapeutics. MarketBeat recorded 14 mentions for Centessa Pharmaceuticals and 7 mentions for Astria Therapeutics. Centessa Pharmaceuticals' average media sentiment score of 0.91 beat Astria Therapeutics' score of 0.69 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Astria Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CNTA or ATXS more profitable? Astria Therapeutics' return on equity of -43.58% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Centessa PharmaceuticalsN/A -52.13% -38.01% Astria Therapeutics N/A -43.58%-29.36% Which has higher earnings and valuation, CNTA or ATXS? Astria Therapeutics has lower revenue, but higher earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Astria Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentessa Pharmaceuticals$6.85M338.61-$151.09M-$1.53-11.50Astria TherapeuticsN/AN/A-$72.89M-$2.09-4.57 Does the MarketBeat Community believe in CNTA or ATXS? Astria Therapeutics received 536 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 72.90% of users gave Astria Therapeutics an outperform vote while only 56.86% of users gave Centessa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCentessa PharmaceuticalsOutperform Votes2956.86% Underperform Votes2243.14% Astria TherapeuticsOutperform Votes56572.90% Underperform Votes21027.10% Do analysts rate CNTA or ATXS? Centessa Pharmaceuticals presently has a consensus price target of $25.83, indicating a potential upside of 46.78%. Astria Therapeutics has a consensus price target of $25.60, indicating a potential upside of 168.06%. Given Astria Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Astria Therapeutics is more favorable than Centessa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Astria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 SummaryAstria Therapeutics beats Centessa Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Ad Porter & CompanyHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXS vs. The Competition Export to ExcelMetricAstria TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$538.95M$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-4.5710.75135.1817.53Price / SalesN/A287.861,235.42140.39Price / CashN/A56.6540.6537.95Price / Book2.875.394.884.92Net Income-$72.89M$152.04M$118.97M$225.78M7 Day Performance-9.05%-4.32%16.19%-1.58%1 Month Performance4.26%2.80%16.02%6.67%1 Year Performance60.77%17.30%34.95%22.48% Astria Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXSAstria Therapeutics1.873 of 5 stars$9.55-1.2%$25.60+168.1%+52.8%$538.95MN/A-4.5730Short Interest ↑CNTACentessa Pharmaceuticals3.331 of 5 stars$16.29-1.7%$25.83+58.6%+147.5%$2.15B$6.85M-10.8372Insider TradeNews CoverageRXRXRecursion Pharmaceuticals2.5201 of 5 stars$7.46+7.3%$9.25+24.0%-26.6%$2.14B$44.58M-4.85400High Trading VolumeAPGEApogee Therapeutics2.729 of 5 stars$47.07+5.8%$83.88+78.2%+110.6%$2.12BN/A-18.3991Insider TradeShort Interest ↑News CoverageIBRXImmunityBio2.2677 of 5 stars$3.02+5.2%$17.38+475.3%-34.2%$2.10B$7.33M-3.36590WVEWave Life Sciences4.9175 of 5 stars$13.54+0.7%$22.22+64.1%+227.7%$2.07B$113.31M-12.11240Positive NewsMIRMMirum Pharmaceuticals4.1617 of 5 stars$42.32-0.3%$57.73+36.4%+22.1%$2.03B$307.03M-21.01140News CoverageAKROAkero Therapeutics3.9591 of 5 stars$29.04+0.5%$46.83+61.3%+33.6%$2.03BN/A-7.7030Short Interest ↓TARSTarsus Pharmaceuticals0.5082 of 5 stars$51.44-2.0%$54.20+5.4%+179.6%$1.97B$17.45M-13.7850Positive NewsAMPHAmphastar Pharmaceuticals4.8676 of 5 stars$40.90-3.2%$60.33+47.5%-27.8%$1.97B$644.40M14.081,761Insider TradeIRONDisc Medicine3.2945 of 5 stars$65.45+0.9%$87.50+33.7%+10.7%$1.95BN/A-16.3078 Related Companies and Tools Related Companies Centessa Pharmaceuticals Competitors Recursion Pharmaceuticals Competitors Apogee Therapeutics Competitors ImmunityBio Competitors Wave Life Sciences Competitors Mirum Pharmaceuticals Competitors Akero Therapeutics Competitors Tarsus Pharmaceuticals Competitors Amphastar Pharmaceuticals Competitors Disc Medicine Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATXS) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATXS Stock Alerts